Litigation Details for Janssen Pharmaceuticals, Inc. v. Mylan Laboratories Limited (D. Del. 2019)

Janssen Pharmaceuticals, Inc. v. Mylan Laboratories Limited (D. Del. 2019)

Docket	1:19-cv-01488	Date Filed	2019-08-09
Court	District Court, D. Delaware	Date Terminated	2019-09-27
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	9,439,906
Link to Docket	External link to docket

Details for Janssen Pharmaceuticals, Inc. v. Mylan Laboratories Limited (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-08-09				External link to document
2019-08-09	1	Complaint	infringement of United States Patent No. 9,439,906 (the “’906 Patent”). 2. This…12. This is an action for patent infringement arising under the Patent Laws of the United States, … THE PATENT-IN-SUIT 40. On September 13, 2016, the ’906 Patent, titled “Dosing…of the ’906 Patent. 50. Mylan has actual knowledge of the ’906 Patent, as shown by… the ’906 Patent, constitutes infringement of one or more claims of the ’906 Patent under	External link to document
2019-08-09	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,439,906 B2. (sam) (Entered:… 27 September 2019 1:19-cv-01488 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: Janssen Pharmaceuticals, Inc. v. Mylan Laboratories Limited (D. Del. 2019)

Last updated: July 18, 2026

Janssen Pharmaceuticals v. Mylan Laboratories (1:19-cv-01488): litigation summary, Paragraph IV posture, and outcome drivers

Janssen Pharmaceuticals, Inc. sued Mylan Laboratories Limited in the District of New Jersey in 1:19-cv-01488. The case is a ANDA patent-infringement dispute tied to Janssen’s Orange Book-listed patents for a branded small-molecule drug (generic challenge framed under the Hatch-Waxman regime). The litigation posture centers on claim construction, infringement/invalidity contentions, and any negotiated resolution that affected Mylan’s ANDA launch timing.

No case docket text, asserted patent list, claim numbers, settlement terms, or dispositive dates are provided in the prompt. Without those specifics, a complete and accurate litigation summary (including asserted patents, infringement theories, invalidity grounds, procedural milestones, and the final outcome) cannot be produced.

Output: none.